Now FDA ClearedTandem Mobi Tubeless
Get ready for the only pump that's tubed or tubeless1
Tandem Mobi Tubeless combines the freedom of a tubeless design with up to 7 days of wear.* Powered by Control-IQ+ technology, it can deliver better control for people coming from daily injections.2
Tubeless Design
Experience the freedom of tubeless automated insulin delivery.
Up to 7 Days of Wear*
Fewer needles means more time for you and less time managing diabetes.
Control-IQ+ Technology
Better control, #1 rated in clinical outcomes by healthcare providers.3
Tandem Mobi Tubeless is a new infusion set and cartridge that will work with existing Tandem Mobi pumps. Tandem Mobi customers can simply change their supply order. Supplies will only be available to customers with pharmacy coverage. Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi in the U.S. is planned for the first half of 2027.
A Tandem Diabetes Care Specialist can help.
Tandem Mobi is the only system that gives you the flexibility of tubed or tubeless wear,1 creating convenient diabetes management that matches your needs.
* Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use.
References
Note: Study was conducted using t:slim X2 insulin pump with Control-IQ technology and Dexcom G6.
1. As of Nov., 2026. Data on file, Tandem Diabetes Care.
2. Breton MD, et al. N Engl J Med. 2020;383:836-845.
3. Seagrove Partners HCP Perspectives (Devices), September 2026 Insulin Delivery Section N=83.
Important Safety Information
RX ONLY. The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 2 years of age and greater.
Control-IQ+ technology is intended for use with compatible interoperable continuous glucose monitors (iCGM), alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is not a substitute for your own active diabetes management.
Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater. Control-IQ+ technology is intended for use in pregnancy complicated by Type 1 diabetes mellitus, provided the linked CGM system is suitable for use in pregnancy.
WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old. Control-IQ+ technology should also not be used in patients who require less than a total daily insulin dose of 5 units per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed in order for Control-IQ+ technology to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.